2015
Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review
Roque DM, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Nelson WK, Santin AD. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review. Gynecologic Oncology 2015, 137: 392-400. PMID: 25792179, DOI: 10.1016/j.ygyno.2015.03.008.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabDisease-Free SurvivalDrug Administration ScheduleEpothilonesFallopian Tube NeoplasmsFemaleHumansMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsPeritoneal NeoplasmsProspective StudiesRetrospective StudiesConceptsObjective response rateFallopian tube cancerWeekly ixabepiloneOvarian cancerConcurrent bevacizumabRetrospective reviewMedian PFS/OSSimilar objective response ratesWarrants further prospective studySingle-institution retrospective reviewCA-125 criteriaPFS/OSTreatment of recurrentKaplan-Meier methodFurther prospective studiesBiweekly bevacizumabMedian PFSAcceptable toxicityGrade 1/2Median durationOverall survivalPrior linesClinical outcomesProspective studyUterine cancer
2014
Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: An institutional experience
Roque D, Schwab C, English D, Ratner E, Silasi D, Azodi M, Rutherford T, Schwartz P, Santin A. Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: An institutional experience. Gynecologic Oncology 2014, 133: 69. DOI: 10.1016/j.ygyno.2014.03.187.Peer-Reviewed Original Research
2012
Weekly ixabepilone with or without concurrent bevacizumab in the treatment of recurrent endometrial cancer.
Roque D, Ratner E, Silasi D, Azodi M, Schwartz P, Rutherford T, Santin A. Weekly ixabepilone with or without concurrent bevacizumab in the treatment of recurrent endometrial cancer. Journal Of Clinical Oncology 2012, 30: e15526-e15526. DOI: 10.1200/jco.2012.30.15_suppl.e15526.Peer-Reviewed Original ResearchRecurrent endometrial cancerConcurrent bevacizumabEndometrial cancerWeekly ixabepiloneDemographic/disease characteristicsCycles of ixabepiloneMedian overall survivalPR/SDPhase II studyExperienced progressionQ21 daysDisease stabilizationGastrointestinal toxicityFirst recurrenceII studyMedian survivalOverall survivalPartial responseCA 125Median timeDisease characteristicsDosing strategiesInstitutional experienceBevacizumabIxabepilone